Brainstorm Cell Therapeutics (BCLI) Given a $9.00 Price Target at Maxim Group
The brokerage currently has a "buy" rating on the biotechnology company's stock. Maxim Group's price target suggests a potential upside of 171.08% from the company's previous close.
from Biotech News
Комментариев нет:
Отправить комментарий